Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Abbisko Cayman Limited ( (HK:2256) ) is now available.
Abbisko Cayman Limited announced a cooperation agreement between its subsidiary, Abbisko Therapeutics, and Shanghai Allist Pharmaceuticals to explore the combination of Abbisko’s ABSK043 and Allist’s glecirasib for treating non-small cell lung cancer (NSCLC) patients with KRAS-G12C mutation. This collaboration aims to leverage the promising results of ABSK043, which has shown favorable safety and anti-tumor activity in early trials, potentially enhancing Abbisko’s position in the oncology market and offering new hope for NSCLC treatment.
More about Abbisko Cayman Limited
Abbisko Cayman Limited operates in the pharmaceutical industry, focusing on the development of novel oncology drugs. Its subsidiary, Abbisko Therapeutics, is engaged in creating innovative treatments, including the investigational oral PD-L1 inhibitor ABSK043, aimed at addressing unmet medical needs in cancer treatment.
YTD Price Performance: 71.96%
Average Trading Volume: 4,110,649
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.38B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.